Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

D PetersSponsor

24 cosponsors · 16 D, 8 R

2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019

What it does: CRS summary · Introduced in House · Jul 16, 2019

Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2020 and as adjusted based on a specified fee schedule factor in each year thereafter.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019

Latest action (Jul 17, 2019): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Jul 16, 2019

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.